| Allele-specific chromatin recruitment and therapeutic vulnerabilities of ESR1 activating mutations R Jeselsohn, JS Bergholz, M Pun, MI Cornwell, W Liu, A Nardone, T Xiao, ... Cancer cell 33 (2), 173-186. e5, 2018 | 237 | 2018 |
| COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19 L Yang, W Liu, X Yu, M Wu, JM Reichert, M Ho Antibody therapeutics 3 (3), 205-212, 2020 | 105 | 2020 |
| Estrogen receptor signaling is reprogrammed during breast tumorigenesis D Chi, H Singhal, L Li, T Xiao, W Liu, M Pun, R Jeselsohn, H He, E Lim, ... Proceedings of the National Academy of Sciences 116 (23), 11437-11443, 2019 | 73 | 2019 |
| Changing character of rainfall in eastern China, 1951–2007 JA Day, I Fung, W Liu Proceedings of the National Academy of Sciences 115 (9), 2016-2021, 2018 | 66 | 2018 |
| A distinct chromatin state drives therapeutic resistance in invasive lobular breast cancer A Nardone, X Qiu, S Spisak, Z Nagy, A Feiglin, A Feit, G Cohen Feit, Y Xie, ... Cancer research 82 (20), 3673-3686, 2022 | 7 | 2022 |
| CRISPR screening in human hematopoietic stem and progenitor cells reveals an enrichment for tumor suppressor genes within chromosome 7 commonly deleted regions JT Baeten, W Liu, IC Preddy, N Zhou, ME McNerney Leukemia 36 (5), 1421-1425, 2022 | 4 | 2022 |
| Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer YC Cheng, S Stein, A Nardone, W Liu, W Ma, G Cohen, C Guarducci, ... Cancer Research Communications 3 (11), 2331-2344, 2023 | 2 | 2023 |
| Reply to Li et al: Late 20th-century drought in northern China reflects influence of global warming, aerosols, and natural variability JA Day, IY Fung, W Liu Proceedings of the National Academy of Sciences 115 (36), E8329-E8329, 2018 | 1 | 2018 |
| Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer C Guarducci, A Nardone, D Russo, Z Nagy, C Heraud, A Grinshpun, ... Clinical Cancer Research 30 (9), 1889-1905, 2024 | | 2024 |
| CUX1 dosage-dependent regulation of hematopoietic stem and progenitor cells W Liu, S Konecki, T Martinez, M McNerney Cancer Research 82 (12_Supplement), 3159-3159, 2022 | | 2022 |
| Mathematical modeling identifies optimum palbociclib dosing schedules for the treatment of estrogen receptor-positive (ER plus) breast cancer patients S Stein, A Nardone, W Liu, G Cohen, C Guarducci, M Brown, R Jeselsohn, ... CANCER RESEARCH 80 (11), 63-63, 2020 | | 2020 |
| Abstract B16: Mathematical modeling identifies optimum palbociclib dosing schedules for the treatment of estrogen receptor-positive (ER+) breast cancer patients S Stein, A Nardone, W Liu, G Cohen, C Guarducci, M Brown, R Jeselsohn, ... Cancer Research 80 (11_Supplement), B16-B16, 2020 | | 2020 |
| CUX1 Regulates Human Hematopoietic Stem Cell Chromatin Accessibility via the BAF Complex W Liu, JL Kurkewich, A Stoddart, S Khan, D Anandan, AN Gaubil, ... Available at SSRN 4531949, 0 | | |
| Selective CDK7 Inhibition Has Dual Activity in Treatment Resistant Estrogen Receptor Positive Breast Cancer C Guarducci, A Nardone, D Russo, Z Nagy, C Heraud, MJ Leventhal, ... | | |
Jesse A. DayGraduate Student, Department of Earth and Planetary Science, University of California Berkeley在 berkeley.edu 的电子邮件经过验证
